Sumary of Oxford/AstraZeneca jab could have causal link to rare blood clots, say UK experts:
- Drug safety experts in the UK believe there could be a causal link between the Oxford/AstraZeneca Covid jab and very rare blood clots but say vaccination programmes must continue, with risk mitigation for women under 55..
- Prof Saad Shakir, the director of the drug safety research unit (DSRU) at Southampton University, said the evidence accumulated in Europe and the UK “is consistent with causality”..
- The Southampton University unit has shared its analysis of the cases of cerebral venous sinus thrombosis in Europe and the UK with the regulators..
- The UK Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) are doing their own reviews and considering whether any action should be taken..
- On Tuesday, the EMA denied it has already established a causal connection between the vaccine and the rare blood clotting syndrome after a senior official from the agency said there was a link..
- Marco Cavaleri, the EMA head of vaccines, had earlier told Italy Il Messaggero newspaper that in his opinion “we can say it now, it is clear there is a link with the vaccine … but we still do not know what causes this reaction”..
- The DSRU at Southampton University looked at cases of thrombosis (blood clotting inside the arteries) linked to thrombocytopenia (a reduction in blood platelets that usually causes bleeding but in rare cases results in clotting) and concluded that they were linked to the AstraZeneca vaccine..
- In Germany, there was one event of cerebral venous thrombosis for every 46,512 women vaccinated and one female death associated with this condition for every 149,860 vaccine doses given to women of any age….